Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Burlet, N.
LECART, Marie-Paule ; Centre Hospitalier Universitaire de Liège - CHU > Algologie - soins palliatifs
Language :
English
Title :
Ibandronate: a new perspective in the treatment of osteoporosis
Kanis JA, Delmas P, Burckhardt P et al. Guidelines for diagnosis and management of osteoporosis - the European Foundation for Osteoporosis and Bone Disease. Osteoporos. Int. 7, 390-406 (1997).
Melton LJ III. Adverse outcomes of osteoporotic fractures in the general population. J. Bone Miner. Res. 18, 1139-1141 (2003).
Ismail AA, O'Neill TW, Cooper C et al. Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos. Int. 8, 291-297 (1998).
Cauley JA, Thompson DE, Ensrud KC et al. Risk of mortality following clinical fractures. Osteoporos. Int. 11, 556-561 (2000).
Madhok R, Kerr H, Capel HA. Recent advances: rheumatology. Br. Med. J. 321, 882-885 (2000).
Lippuner K, von Overbeck J, Perrelet R et al. Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporos. Int. 7, 414-425 (1997).
Ray NF, Chan JK, Thamer M et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J. Bone Miner. Res. 12, 24-35 (1997).
International Osteoporosis Foundation. Osteoporosis in the European Community: a call to action. International Osteoporosis Foundation, Switzerland (2001).
Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348, 1535-1541 (1996).
Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282, 1344-1352 (1999).
Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. 11, 83-91 (2000).
Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79, 1693-1700 (1994).
Harris ST, Gertz BJ, Genant HK et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodelling in early postmenopausal women. J. Clin. Endocrinol. Metab. 76, 1399-1406 (1993).
Raisz L, Smith JA, Trahiotis M et al. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos. Int. 11, 615-620 (2000).
Chesnut CH, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 19, 1241-1249 (2004).
McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. 344, 333-340 (2001).
Pols HA, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos. Int. 9, 461-468 (1999).
Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin. Ther. 19, 1446-1457 (1997).
Sung JC, Nichol MB, Venturini F et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am. J. Manag. Care 4, 1421-1430 (1998).
Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 279, 1458-1462 (1998).
Wogen J, Kreilick CA, Livornese RC et al. Patient adherence with amlodipine, lisinopril or valsartan therapy in a usual-care setting. J. Manag. Care Pharm. 9, 424-429 (2003).
Irvine J, Baker B, Smith J et al. Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study - Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Psychosom. Med. 61, 566-575 (1999).
Schweizer RT, Rovelli M, Palmeri D et al. Non-compliance in organ transplant recipients. Transplantation 49, 374-377 (1990).
Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 3, 338-342 (2002).
Zygmunt A, Olfson M, Boyer CA et al. Interventions to improve medication adherence in schizophrenia. Am. J. Psychiatry 159, 1653-1664 (2002).
Sullivan S, Kreling D, Hazlet TH. Non-compliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J. Res. Pharmac. Econom. 2, 19-33 (1990).
Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am. J. Med. 102, 43-49 (1997).
Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. J. Bone Miner. Res. 15, S529 (2001).
Tosteson AN, Grove MR, Hammond CS et al. Early discontinuation of treatment for osteoporosis. Am. J. Med. 115, 209-216 (2003).
Venturini F, Nichol MB, Sung JC et al. Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann. Pharmacother. 33, 281-288 (1999).
Roldán EJA, Negri AL, Gador SA. Short-term compliance to daily alendronate treatment in 1877 patients with osteoporosis - the ECMO study. J. Bone Miner. Res. 15, SU411 (2000).
Negri AL. Short-term compliance with alendronate 70 mg in patients with osteoporosis: the ECMO trial. Bone 23(Suppl. 5) (2003) Abstract P487.
Bandeira F, Kayath M, Marques-Neto J et al. Patients' clinical features and compliance associated with raloxifene or alendronate after a six-month observational Brazilian study. J. Bone Miner. Res. 1(Suppl. 2) (2003) Abstract M352.
Ettinger MP, Gallagher R, Amonkar MM et al. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum. 50(Suppl.) (2004) Abstract 1325.
Cramer JA, Amonkar MM, Hebborn A et al. Assessing the relationship between bisphosphonate dosing regimen and treatment adherence among postmenopausal osteoporotic women. Arthritis Rheum. 50(Suppl.) (2004) Abstract 677.
Eastell R, Garnero P, Vrijens B et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif. Tissue Int. 72 (2003) Abstract P297.
Yood RA, Emani S, Reed JI et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos. Int. 14, 965-968 (2003).
Finigan J, Bainbridge PR, Eastell R. Adherence to osteoporosis therapies. Osteoporos. Int. 12, S48-S49 (2001) Abstract P110.
Sebaldt RJ, Shane LG, Pham B et al. Longer term effectiveness outcomes of nonpersistence with daily regimen bisphosphonates therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos. Int. 15(Suppl. 1), S107 (2004).
Caro J, Huybrechts K, Ishak K, Naujoks C. The impact of adherence to osteoporosis therapy on fracture rates in actual practice. Value Health 5, HP4 (2002).
McCombs JS, Thiebaud P, McLaughlin-Miley C et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48, 271-287 (2004).
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23, 1296-1310 (2001).
de Klerk E, van der Heijde D, van der Tempel H et al. Patient compliance with antirheumatic drug therapy in RA. Arthritis Rheum. 42, S237 (1999).
Simon JA, Lewiecki EM, Smith ME et al. Patient preference for once-weekly alendronate 70mg versus once-daily alendronate 10mg: a multicenter, randomized, open-label, cross-over study. Clin. Ther. 24, 1871-1886 (2002).
Bone HG, Adami S, Rizzoli R et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin. Ther. 22, 15-28 (2000).
Peter CP, Handt LK, Smith SM. Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig. Dis. Sci. 43, 1998-2002 (1998).
Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos. Int. 14, 259-262 (2003).
Muhlbauer RC, Bauss F, Schenk R et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 6, 1003-1011 (1991).
Adami S, Viapiana O. Ibandronate: new option in the treatment of osteoporosis. Drugs Today (Barc.) 39, 877-886 (2003).
Chapurlat RD, Delmas PD. Review of ibandronate in the treatment of osteoporosis. Expert Opin. Pharmacother. 4, 391-396 (2003).
Papapoulos SE. Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis. Int. J. Clin. Pract. 57, 417-422 (2003).
Schimmer RC, Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three Phase II studies. Clin. Ther. 25, 19-34 (2003).
Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of daily oral dosing versus intermittent dosing in postmenopausal osteoporosis. J. Bone Miner. Res. 16, 1871-1878 (2001).
F. Hoffmann-La Roche Ltd. Data on file.
Felsenberg D, Miller PD, Gilbride J, Schimmer RC, Papapoulos SE. Oral daily ibandronate rapidly reduces the risk of new mild, moderate and severe vertebral fractures after 1, 2 and 3 years. J. Bone Miner. Res. 18 (Suppl. 2), S91 (2003).
Delmas PD, Emkey R, Gilbride J, Schimmer RC, Leishman B, Rosen CJ. Oral ibandronate has a similar gastrointestinal (GI) safety profile to placebo in patients with a history of GI disorders or receiving concomitant NSAIDS. Osteoporos. Int. 14 (Suppl. 7), S74 (2003).
Reginster J-Y, Weise C, Wilson KM, Schimmer RC. Oral monthly ibandronate in postmenopausal bone loss: results from the Monthly Oral Pilot Study (MOPS). J. Bone Miner. Res. 18(Suppl. 2), S373 (2003).
Schnitzer T, Bone HG, Crepaldi G et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12, 1-12 (2000).
Brown J, Kendler D, McClung M et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif. Tissue Int. 71, 103-111 (2002).
Gieschke R, Reginster JY. Successful prediction of biomarker response to oral monthly ibandronate. Osteoporos. Int. 15(Suppl. 1), S97 (2004).
Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br. J. Cancer 90, 1133-1137 (2004).
Cooper C, Delmas P, Coutant K et al. Oral monthly ibandronate in postmenopausal osteoporosis: rationale and design of the MOBILE study. Osteoporos. Int. 14(Suppl. 7), S55 (2003).
Ravn P, Overgaard K, Huang C, Ross PD, Green D, McClung M. Comparison of bone densitometry of the phalanges, distal forearm and axial skeleton in early postmenopausal women participating in the EPIC Study. Osteoporos. Int. 6, 308-313 (1996).
Russell RG. Understanding intermittent therapy: potency and persistence. Osteoporos. Int. 3(Suppl. 3), S77 (2002).
Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N. Engl. J. Med. 349, 1676-1679 (2003).
Markowitz GS, Fine PL, Stack JI et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 64, 281-289 (2003).
Smith SY, Recker RR, Hannan M, Muller R, Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32, 45-55 (2003).
Pecherstorfer M, Ludwig H, Schlosser K et al. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J. Bone Miner. Res. 11, 587-593 (1996).
Thiébaud D, Burckhardt P, Kriegbaum H et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am. J. Med. 103, 298-307 (1997).
Recker RR, Stakkestad JA, Chesnut CH et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34, 890-899 (2004).
Adami S, Felsenberg D, Christiansen C et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34, 881-889 (2004).
Harris ST, Eriksen EF, Davidson M et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 86, 1890-1897 (2001).
Ringe J, Dorst A, Faber H et al. Intermittent i.v. ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos. Int. 14, 801-807 (2003).
Adami S, Recker R, Reid DM et al. Intermittent ibandronate injections in postmenopausal osteoporosis: rationale and design of the Dosing IntraVenous Administration (DIVA) study. Osteoporos. Int. 14(Suppl. 7) (2003) Abstract P217.
